Visceral Adipose Tissue Mesothelial Cells: Living on the Edge or Just Taking Up Space?

Trends in Endocrinology and Metabolism

Volumn 26, Issue 10, 2015, Pages 515-523

  Gupta, Olga T ^a   Gupta, Rana K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adipocyte development; Adipose tissue; Fibrosis; Inflammation; Mesothelial cells

Indexed keywords

ADIPOCYTE; BODY FAT DISTRIBUTION; FIBROSIS; HUMAN; HYPERPLASIA; HYPERTROPHY; IMMUNOMODULATION; INFLAMMATION; INTRAABDOMINAL FAT; MESOTHELIUM; MESOTHELIUM CELL; METABOLISM; NONHUMAN; OBESITY; PERITONEUM CELL; PRIORITY JOURNAL; REVIEW; TISSUE GROWTH; TISSUE REGENERATION; ADIPOSE TISSUE; ANIMAL;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; FIBROSIS; HUMANS;

EID: 84942089773     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.07.003     Document Type: Review

References (80)

1. Appleton S.L., et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013, 36:2388-2394.
2. Voulgari C., et al. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J. Am. Coll. Cardiol. 2011, 58:1343-1350.
3. Denis G.V., Obin M.S. 'Metabolically healthy obesity': origins and implications. Mol. Aspects Med. 2013, 34:59-70.
4. Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol. Rev. 1994, 74:761-811.
5. Karastergiou K., et al. Sex differences in human adipose tissues - the biology of pear shape. Biol. Sex Differ. 2012, 3:13.
6. Palmer B.F., Clegg D.J. The sexual dimorphism of obesity. Mol. Cell. Endocrinol. 2015, 402:113-119.
7. Nielsen S., et al. Splanchnic lipolysis in human obesity. J. Clin. Invest. 2004, 113:1582-1588.
8. Tran T.T., et al. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 2008, 7:410-420.
9. Hocking S.L., et al. Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice. Diabetologia 2015, 58:1587-1600.
10. Macotela Y., et al. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 2009, 58:803-812.
11. Gesta S., et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6676-6681.
12. Karastergiou K., et al. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J. Clin. Endocrinol. Metab. 2013, 98:362-371.
13. Chau Y.Y., et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat. Cell Biol. 2014, 16:367-375.
14. Jiang Y., et al. Independent stem cell lineages regulate adipose organogenesis and adipose homeostasis. Cell Rep. 2014, 9:1007-1022.
15. Wang Q.A., et al. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med. 2013, 19:1338-1344.
16. Lee M.J., et al. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 2013, 34:1-11.
17. Sun K., et al. Adipose tissue remodeling and obesity. J. Clin. Invest. 2011, 121:2094-2101.
18. Kloting N., Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev. Endocr. Metab. Disord. 2014, 15:277-287.
19. Gealekman O., et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011, 123:186-194.
20. Hardy O.T., et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg. Obes. Relat. Dis. 2011, 7:60-67.
21. Gustafson B., et al. Insulin resistance and impaired adipogenesis. Trends Endocrinol. Metab. 2015, 26:193-200.
22. Gustafson B., et al. Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4. Diabetes 2013, 62:2997-3004.
23. Gustafson B., et al. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E999-E1003.
24. Larsen P.J., Tennagels N. On ceramides, other sphingolipids and impaired glucose homeostasis. Mol. Metab. 2014, 3:252-260.
25. Perry R.J., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014, 510:84-91.
26. Kloting N., et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E506-E515.
27. Sun K., et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun. 2014, 5:3485.
28. Hardy O.T., et al. What causes the insulin resistance underlying obesity?. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19:81-87.
29. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
30. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013, 17:851-859.
31. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
32. Grant R., et al. Quantification of adipose tissue leukocytosis in obesity. Methods Mol. Biol. 2013, 1040:195-209.
33. Strissel K.J., et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
34. Grant R.W., Dixit V.D. Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015, 23:512-518.
35. Wernstedt Asterholm I., et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014, 20:103-118.
36. McNelis J.C., Olefsky J.M. Macrophages, immunity, and metabolic disease. Immunity 2014, 41:36-48.
37. Dandona P., et al. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
38. Yung S., Chan T.M. Mesothelial cells. Perit. Dial. Int. 2007, 27(Suppl. 2):S110-S115.
39. Lachaud C.C., et al. EGF-induced adipose tissue mesothelial cells undergo functional vascular smooth muscle differentiation. Cell Death Dis. 2014, 5:e1304.
40. Mutsaers S.E. The mesothelial cell. Int. J. Biochem. Cell Biol. 2004, 36:9-16.
41. Ksiazek K. Mesothelial cell: a multifaceted model of aging. Ageing Res. Rev. 2013, 12:595-604.
42. Mutsaers S.E., et al. Mesothelial cells in tissue repair and fibrosis. Front. Pharmacol. 2015, 6:113.
43. Yung S., Chan T.M. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm. 2012, 2012:484167.
44. Mikula-Pietrasik J., et al. Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo. Cancer Lett. 2014, 355:310-315.
45. Maciver A.H., et al. Intra-abdominal adhesions: cellular mechanisms and strategies for prevention. Int. J. Surg. 2011, 9:589-594.
46. Oparka R., et al. Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. J. Clin. Pathol. 2011, 64:313-318.
47. Takahashi K., et al. Cobblestone monolayer cells from human omental adipose tissue are possibly mesothelial, not endothelial. In Vitro Cell. Dev. Biol. 1989, 25:109-111.
48. Darimont C., et al. Contribution of mesothelial cells in the expression of inflammatory-related factors in omental adipose tissue of obese subjects. Int. J. Obes. (Lond.) 2008, 32:112-120.
49. Topley N., et al. Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. Am. J. Pathol. 1993, 142:1876-1886.
50. Zemel D., et al. Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation. Nephrol. Dial. Transplant. 1994, 9:169-174.
51. Kim C.S., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes. (Lond.) 2006, 30:1347-1355.
52. Bruun J.M., et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E8-E13.
53. Rotter V., et al. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 2003, 278:45777-45784.
54. Topley N., et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int. 1993, 43:226-233.
55. Shi H., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
56. Colmont C.S., et al. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of toll-like receptors. Nephrol. Dial. Transplant. 2011, 26:4079-4090.
57. Kato S., et al. Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of toll-like receptor 4. J. Am. Soc. Nephrol. 2004, 15:1289-1299.
58. - intraperitoneal mesothelial-like cells inhibit T cell activation by production of arginase I. Cell. Immunol. 2014, 288:8-14.
59. Yanez-Mo M., et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N. Engl. J. Med. 2003, 348:403-413.
60. Aroeira L.S., et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 2007, 18:2004-2013.
61. Rinkevich Y., et al. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat. Cell Biol. 2012, 14:1251-1260.
62. Asahina K., et al. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology 2011, 53:983-995.
63. Cano E., et al. Wt1-expressing progenitors contribute to multiple tissues in the developing lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 305:L322-L332.
64. Carmona R., et al. Cells derived from the coelomic epithelium contribute to multiple gastrointestinal tissues in mouse embryos. PLoS ONE 2013, 8:e55890.
65. Martinez-Estrada O.M., et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat. Genet. 2010, 42:89-93.
66. Que J., et al. Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16626-16630.
67. Wilm B., et al. The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development 2005, 132:5317-5328.
68. Sun K., et al. Fibrosis and adipose tissue dysfunction. Cell Metab. 2013, 18:470-477.
69. Kim M., et al. ERα upregulates Phd3 to ameliorate HIF-1 induced fibrosis and inflammation in adipose tissue. Mol. Metab. 2014, 3:642-651.
70. Balogh P., et al. Estrogen receptor alpha is expressed in mesenteric mesothelial cells and is internalized in caveolae upon Freund's adjuvant treatment. PLoS ONE 2013, 8:e79508.
71. Billon N., Dani C. Developmental origins of the adipocyte lineage: new insights from genetics and genomics studies. Stem Cell Rev. 2012, 8:55-66.
72. Berry R., et al. Weighing in on adipocyte precursors. Cell Metab. 2014, 19:8-20.
73. Seale P., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454:961-967.
74. Liu Q., et al. Epicardium-to-fat transition in injured heart. Cell Res. 2014, 24:1367-1369.
75. Lansley S.M., et al. Mesothelial cell differentiation into osteoblast- and adipocyte-like cells. J. Cell. Mol. Med. 2011, 15:2095-2105.
76. Lachaud C.C., et al. Functional vascular smooth muscle-like cells derived from adult mouse uterine mesothelial cells. PLoS ONE 2013, 8:e55181.
77. Tang W., et al. White fat progenitor cells reside in the adipose vasculature. Science 2008, 322:583-586.
78. Sanchez-Gurmaches J., Guertin D.A. Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed. Nat. Commun. 2014, 5:4099.
79. Loureiro J., et al. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS ONE 2013, 8:e61165.
80. Liu L., et al. Tamoxifen reduces fat mass by boosting reactive oxygen species. Cell Death Dis. 2015, 6:e1586.